Skip to main content
Erschienen in:

18.06.2024 | Morbus Crohn | Zertifizierte Fortbildung

Chronisch-entzündliche Darmerkrankungen

Update CED: Sonografische Diagnostik und neue medikamentöse Therapien

verfasst von: Dr. med. Michelle A. Klose, Prof. Dr. med. Klaus R. Herrlinger, Chefarzt, Prof. Dr. med. Eduard F. Stange

Erschienen in: Gastro-News | Ausgabe 3/2024

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Das Spektrum der medikamentösen Therapie chronisch-entzündlicher Darmerkrankungen wird immer komplexer, da laufend neue Substanzen nach entsprechendem Wirknachweis zugelassen werden und auf den Markt kommen. Die Leitlinien der DGVS und der ECCO müssen rascher denn je aktualisiert werden, sind aber trotzdem nicht immer auf dem neuesten Stand und bieten nach wie vor keine Priorisierung der Therapieoptionen. Dieses Update geht nach einem Blick auf die Verlaufsdiagnostik auf die aktuell neuen Therapeutika ein, sowie auf die Wirkstoffe in der „Pipeline“.
Literatur
1.
Zurück zum Zitat Herrlinger KR, Stange EF. Therapie-Update Morbus Crohn. GASTRO-NEWS. 2021;08(5):26-33 Herrlinger KR, Stange EF. Therapie-Update Morbus Crohn. GASTRO-NEWS. 2021;08(5):26-33
2.
Zurück zum Zitat Herrlinger KR, Stange EF. Management und Therapie des Morbus Crohn. GASTRO-NEWS. 2022;09(4) Herrlinger KR, Stange EF. Management und Therapie des Morbus Crohn. GASTRO-NEWS. 2022;09(4)
3.
Zurück zum Zitat Herrlinger KR, Stange EF. Therapie der Colitis ulcerosa. GASTRO-NEWS. 2022;09(5) Herrlinger KR, Stange EF. Therapie der Colitis ulcerosa. GASTRO-NEWS. 2022;09(5)
4.
Zurück zum Zitat Turner D et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160:1570-83 Turner D et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160:1570-83
5.
Zurück zum Zitat Desai M, Campbell C, Perisetti A et al. The Environmental Impact of Gastrointestinal Procedures: A Prospective Study of Waste Generation, Energy Consumption, and Auditing in an Endoscopy Unit. Gastroenterology. 2024;166:496-502.e3 Desai M, Campbell C, Perisetti A et al. The Environmental Impact of Gastrointestinal Procedures: A Prospective Study of Waste Generation, Energy Consumption, and Auditing in an Endoscopy Unit. Gastroenterology. 2024;166:496-502.e3
6.
Zurück zum Zitat Klose MA, Becker A, Blank V et al. Role of patient and staff mobility in scope 3 emissions in GI endoscopy. Gut. 2024 Feb 28:gutjnl-2024-332041 Klose MA, Becker A, Blank V et al. Role of patient and staff mobility in scope 3 emissions in GI endoscopy. Gut. 2024 Feb 28:gutjnl-2024-332041
7.
Zurück zum Zitat Kucharzik T al. ECCO-ESGAR Topical Review on Optimizing Reporting for Cross-Sectional Imaging in Inflammatory Bowel Disease. J Crohns Colitis. 2022:16:523-43 Kucharzik T al. ECCO-ESGAR Topical Review on Optimizing Reporting for Cross-Sectional Imaging in Inflammatory Bowel Disease. J Crohns Colitis. 2022:16:523-43
8.
Zurück zum Zitat Rimola Jet al. Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. Gut. 2022;71:2587-97 Rimola Jet al. Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. Gut. 2022;71:2587-97
9.
Zurück zum Zitat Panés J et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther. 2011;34:125-45 Panés J et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther. 2011;34:125-45
10.
Zurück zum Zitat Geyl S, Guillo L, Laurent V et al. Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):659-67 Geyl S, Guillo L, Laurent V et al. Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):659-67
11.
Zurück zum Zitat Kucharzik T et al. Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease. Clin Gastroenterol Hepatol. 2023;21:153-63.e12 Kucharzik T et al. Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease. Clin Gastroenterol Hepatol. 2023;21:153-63.e12
12.
Zurück zum Zitat Herrlinger KR, Stange EF. To STRIDE or not to STRIDE: a critique of “treat to target” in Crohn´s disease. Expert Rev Gastroenterol Hepatol. 2023;17:1205-19 Herrlinger KR, Stange EF. To STRIDE or not to STRIDE: a critique of “treat to target” in Crohn´s disease. Expert Rev Gastroenterol Hepatol. 2023;17:1205-19
13.
Zurück zum Zitat Allocca M et al. Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn's disease: a prospective cohort study. EClinicalMedicine. 2024;71:102559 Allocca M et al. Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn's disease: a prospective cohort study. EClinicalMedicine. 2024;71:102559
14.
Zurück zum Zitat Maaser C et al. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study. Gut. 2020;69:1629-36 Maaser C et al. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study. Gut. 2020;69:1629-36
15.
Zurück zum Zitat Piazza O Sed N et al. Superior predictive value of transmural over endoscopic severity for colectomy risk in ulcerative colitis: a multicentre prospective cohort study. J Crohns Colitis. 2024;18:291-9 Piazza O Sed N et al. Superior predictive value of transmural over endoscopic severity for colectomy risk in ulcerative colitis: a multicentre prospective cohort study. J Crohns Colitis. 2024;18:291-9
16.
Zurück zum Zitat Honap S et al. Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same? Gastroenterol Hepatol (N Y). 2023;19:727-38 Honap S et al. Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same? Gastroenterol Hepatol (N Y). 2023;19:727-38
17.
Zurück zum Zitat Sandborn WJ et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017;376:1723-36 Sandborn WJ et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017;376:1723-36
18.
Zurück zum Zitat Taxonera C et al. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. Inflamm Bowel Dis. 2022;28:32-40 Taxonera C et al. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. Inflamm Bowel Dis. 2022;28:32-40
19.
Zurück zum Zitat Buisson A et al. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Aliment Pharmacol Ther. 2023;57:676-88 Buisson A et al. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Aliment Pharmacol Ther. 2023;57:676-88
20.
Zurück zum Zitat Straatmijer T et al. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study. Clin Gastroenterol Hepatol. 2023;21:182-91.e2 Straatmijer T et al. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study. Clin Gastroenterol Hepatol. 2023;21:182-91.e2
21.
Zurück zum Zitat Feagan BG, Danese S, Loftus EV et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021; 397:2372-84 Feagan BG, Danese S, Loftus EV et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021; 397:2372-84
22.
Zurück zum Zitat Danese S et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113-28 Danese S et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113-28
23.
Zurück zum Zitat Dalal RS et al. One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study. Am J Gastroenterol. 2024 Apr 1. Dalal RS et al. One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study. Am J Gastroenterol. 2024 Apr 1.
24.
Zurück zum Zitat Ytterberg SR et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386:316-26 Ytterberg SR et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386:316-26
25.
Zurück zum Zitat Scott FL et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016;173:1778-92 Scott FL et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016;173:1778-92
26.
Zurück zum Zitat Karuppuchamy T et al. Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol. 2017;10:162-71 Karuppuchamy T et al. Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol. 2017;10:162-71
27.
Zurück zum Zitat Sandborn WJ et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021;385:1280-91 Sandborn WJ et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021;385:1280-91
28.
Zurück zum Zitat Sandborn WJ et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159-71 Sandborn WJ et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159-71
29.
Zurück zum Zitat Sands BE et al. Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2023;17:2012-25 Sands BE et al. Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2023;17:2012-25
30.
Zurück zum Zitat D'Haens G et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2023;388:2444-55 D'Haens G et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2023;388:2444-55
31.
Zurück zum Zitat Magro F et al. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes. J Crohns Colitis. 2023;17:1457-70 Magro F et al. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes. J Crohns Colitis. 2023;17:1457-70
32.
Zurück zum Zitat Sands BE et al. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm Bowel Dis. 2024 Mar 9:izae024 Sands BE et al. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm Bowel Dis. 2024 Mar 9:izae024
33.
Zurück zum Zitat Loftus EV et al. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2023;388:1966-80 Loftus EV et al. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2023;388:1966-80
34.
Zurück zum Zitat D'Haens G et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015-30 D'Haens G et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015-30
35.
Zurück zum Zitat Ferrante M et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399:2031-46 Ferrante M et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399:2031-46
36.
Zurück zum Zitat Schmitt H et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. Gut. 2019;68:814-28 Schmitt H et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. Gut. 2019;68:814-28
37.
Zurück zum Zitat Alsoud D et al. Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study. Inflammatory Bowel Diseases. 2024 Jan 12:izad315. Alsoud D et al. Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study. Inflammatory Bowel Diseases. 2024 Jan 12:izad315.
38.
Zurück zum Zitat Herrlinger KR et al. Prioritization in inflammatory bowel disease therapy. Expert Rev Gastroenterol Hepatol. 2023;17:753-67 Herrlinger KR et al. Prioritization in inflammatory bowel disease therapy. Expert Rev Gastroenterol Hepatol. 2023;17:753-67
Metadaten
Titel
Chronisch-entzündliche Darmerkrankungen
Update CED: Sonografische Diagnostik und neue medikamentöse Therapien
verfasst von
Dr. med. Michelle A. Klose
Prof. Dr. med. Klaus R. Herrlinger, Chefarzt
Prof. Dr. med. Eduard F. Stange
Publikationsdatum
18.06.2024
Verlag
Springer Medizin
Erschienen in
Gastro-News / Ausgabe 3/2024
Print ISSN: 1869-1005
Elektronische ISSN: 2520-8667
DOI
https://doi.org/10.1007/s15036-024-3714-8

Weitere Artikel der Ausgabe 3/2024

Gastro-News 3/2024 Zur Ausgabe

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?